Treatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting the PD-1/PD-L1 axis and CTLA-4 have been approved for patient treatment, especially in solid tumors. Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer. The endorsement of relatlimab marks a significant milestone in cancer immunotherapy, opening new avenues for combination therapies and enhancing treatment outcomes. However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment.

Alejandra Martínez-Pérez

Rocío Granda-Díaz

Candelaria Aguilar-García

Christian Sordo-Bahamonde

Segundo Gonzalez

Biomarker Research

BIOMARKER RESEARCH 是一本开放获取、同行评审的期刊，涵盖了生物标志物研究的所有方面。生物标志物研究旨在发表与所有生物医学学科的生物标志物研究相关的原始发现、新概念、评论和评论。生物标志物的研究随着个性化医疗和个人健康的发展而迅速发展。在药物发现/开发以及疾病诊断、治疗、预后和预防中，生物标志物的识别和验证在基因组时代发挥着至关重要的作用。凭借从提交到出版的快速周转时间以及读者的在线反馈，BIOMARKER RESEARCH 致力于快速传播新发现和新知识。

Biomarker Research is an open access, peer-reviewed journal that covers all aspects of biomarker research. The journal aims to publish original findings, new concepts, reviews, and commentaries related to biomarker studies across all biomedical disciplines. The research on biomarkers has rapidly evolved alongside the advancements in personalized medicine and individual health. The identification and validation of biomarkers play a crucial role in drug discovery and development, as well as in disease diagnosis, treatment, prognosis, and prevention in the genomic era. Biomarker Research is committed to the rapid dissemination of new discoveries and knowledge, offering a quick turnaround time from submission to publication and encouraging online feedback from readers.

《Biomarker Research》是一本开放获取、同行评审的期刊，涵盖生物标志物研究的各个方面。该期刊旨在发表与所有生物医学学科相关的生物标志物研究的原创发现、新概念、评论和综述。随着个性化医疗和个人健康的快速发展，生物标志物的研究也在不断进步。在药物发现与开发、疾病诊断、治疗、预后和预防中，生物标志物的识别与验证在基因组时代扮演着至关重要的角色。《Biomarker Research》致力于快速传播新发现和新知识，提供从提交到出版的快速周转时间，并鼓励读者在线反馈。

Category	Quartile
医学	2
医学, 医学研究与实验	2
医学, 肿瘤学	2

Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info